-
Je něco špatně v tomto záznamu ?
The effects of the treatment conditions on the dissolution profile of ethylcellulose coated pellets
S. Pavloková, J. Muselík, D. Sabadková, S. Bernatová, O. Samek, D. Neumann, A. Franc,
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články
- MeSH
- celulosa analogy a deriváty chemie MeSH
- chemie farmaceutická MeSH
- glukosa chemie farmakologie MeSH
- hypoglykemie prevence a kontrola MeSH
- léky implantované chemie MeSH
- léky s prodlouženým účinkem MeSH
- polyethylenglykoly chemie MeSH
- pomocné látky chemie MeSH
- povrchové vlastnosti MeSH
- příprava léků metody MeSH
- rozpustnost MeSH
- škrob analogy a deriváty chemie MeSH
- stabilita léku MeSH
- uvolňování léčiv MeSH
- velikost částic MeSH
- vysoká teplota MeSH
- Publikační typ
- časopisecké články MeSH
Due to the additional particle coalescence in the coating, changes in the dissolution profile occur over time in the formulations coated by aqueous ethylcellulose latex. Dry thermal treatment (DT) of the coating can be used as a prevention of this process. Alternatively, it is advisable to take advantage of the synergistic effect of high humidity during wet treatment (WT), which substantially accelerates the film formation. This can be a problem for time-controlled systems, which are based on the coating rupture due to the penetration of water into the core causing the increase in the system volume. This process can begin already during the WT, which may affect the coating adversely. The submitted work was focused on the stability testing of two pellet core compositions: pellets containing swelling superdisintegrant sodium carboxymethyl starch (CMS) and pellets containing osmotically active polyethylene glycol (PEG). Another objective was to identify the treatment/storage condition effects on the pellet dissolution profiles. These pellets are intended to prevent hypoglycemia for patients with diabetes mellitus and therefore, besides the excipients, pellet cores contain 75% or 80% of glucose. The pellet coating is formed by ethylcellulose-based latex, which provides the required lag time (120-360 min). The sample stability was evaluated depending on the pellet core composition (PEG, CMS) for two types of final pellet coating treatment (DT or WT). Scanning electron microscopy and Raman microspectroscopy revealed the penetration of glucose and polyethylene glycol from the core to the PEG pellet surface after WT. For the CMS sample, significant pellet swelling after WT (under the conditions of elevated humidity) was statistically confirmed by the means of stereomicroscopic data evaluation. Therefore, the acceleration of dissolution rate during the stress tests is caused by the soluble substance penetration through the coating in the case of PEG pellets or by dosage form volume increase in the case of CMS pellets. The observed mechanisms can be generally anticipated during the stability testing of the ethylcellulose coated dosage forms. The aforementioned processes do not occur after DT and the pellets are stable in the environment without increased humidity.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19034743
- 003
- CZ-PrNML
- 005
- 20191011105645.0
- 007
- ta
- 008
- 191007s2019 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejps.2019.02.034 $2 doi
- 035 __
- $a (PubMed)30825510
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Pavloková, Sylvie $u Department of Pharmaceutics, University of Veterinary and Pharmaceutical Sciences, Palackeho tr. 1946/1, 612 42 Brno, Czech Republic.
- 245 14
- $a The effects of the treatment conditions on the dissolution profile of ethylcellulose coated pellets / $c S. Pavloková, J. Muselík, D. Sabadková, S. Bernatová, O. Samek, D. Neumann, A. Franc,
- 520 9_
- $a Due to the additional particle coalescence in the coating, changes in the dissolution profile occur over time in the formulations coated by aqueous ethylcellulose latex. Dry thermal treatment (DT) of the coating can be used as a prevention of this process. Alternatively, it is advisable to take advantage of the synergistic effect of high humidity during wet treatment (WT), which substantially accelerates the film formation. This can be a problem for time-controlled systems, which are based on the coating rupture due to the penetration of water into the core causing the increase in the system volume. This process can begin already during the WT, which may affect the coating adversely. The submitted work was focused on the stability testing of two pellet core compositions: pellets containing swelling superdisintegrant sodium carboxymethyl starch (CMS) and pellets containing osmotically active polyethylene glycol (PEG). Another objective was to identify the treatment/storage condition effects on the pellet dissolution profiles. These pellets are intended to prevent hypoglycemia for patients with diabetes mellitus and therefore, besides the excipients, pellet cores contain 75% or 80% of glucose. The pellet coating is formed by ethylcellulose-based latex, which provides the required lag time (120-360 min). The sample stability was evaluated depending on the pellet core composition (PEG, CMS) for two types of final pellet coating treatment (DT or WT). Scanning electron microscopy and Raman microspectroscopy revealed the penetration of glucose and polyethylene glycol from the core to the PEG pellet surface after WT. For the CMS sample, significant pellet swelling after WT (under the conditions of elevated humidity) was statistically confirmed by the means of stereomicroscopic data evaluation. Therefore, the acceleration of dissolution rate during the stress tests is caused by the soluble substance penetration through the coating in the case of PEG pellets or by dosage form volume increase in the case of CMS pellets. The observed mechanisms can be generally anticipated during the stability testing of the ethylcellulose coated dosage forms. The aforementioned processes do not occur after DT and the pellets are stable in the environment without increased humidity.
- 650 _2
- $a celulosa $x analogy a deriváty $x chemie $7 D002482
- 650 _2
- $a chemie farmaceutická $7 D002626
- 650 _2
- $a léky s prodlouženým účinkem $7 D003692
- 650 _2
- $a příprava léků $x metody $7 D004339
- 650 _2
- $a léky implantované $x chemie $7 D004343
- 650 _2
- $a uvolňování léčiv $7 D065546
- 650 _2
- $a stabilita léku $7 D004355
- 650 _2
- $a pomocné látky $x chemie $7 D005079
- 650 _2
- $a glukosa $x chemie $x farmakologie $7 D005947
- 650 _2
- $a vysoká teplota $7 D006358
- 650 _2
- $a hypoglykemie $x prevence a kontrola $7 D007003
- 650 _2
- $a velikost částic $7 D010316
- 650 _2
- $a polyethylenglykoly $x chemie $7 D011092
- 650 _2
- $a rozpustnost $7 D012995
- 650 _2
- $a škrob $x analogy a deriváty $x chemie $7 D013213
- 650 _2
- $a povrchové vlastnosti $7 D013499
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Muselík, Jan $u Department of Pharmaceutics, University of Veterinary and Pharmaceutical Sciences, Palackeho tr. 1946/1, 612 42 Brno, Czech Republic. Electronic address: muselikj@vfu.cz.
- 700 1_
- $a Sabadková, Dana $u Department of Pharmaceutics, University of Veterinary and Pharmaceutical Sciences, Palackeho tr. 1946/1, 612 42 Brno, Czech Republic.
- 700 1_
- $a Bernatová, Silvie $u Institute of Scientific Instruments (ISI), Czech Academy of Sciences, v.v.i., Kralovopolska 147, 612 64 Brno, Czech Republic.
- 700 1_
- $a Samek, Ota $u Institute of Scientific Instruments (ISI), Czech Academy of Sciences, v.v.i., Kralovopolska 147, 612 64 Brno, Czech Republic.
- 700 1_
- $a Neumann, David $u Department of Pediatrics, Faculty of Medicine in Hradec Kralove, Charles University in Prague, University Hospital Hradec Kralove, Czech Republic.
- 700 1_
- $a Franc, Aleš $u Department of Pharmaceutics, University of Veterinary and Pharmaceutical Sciences, Palackeho tr. 1946/1, 612 42 Brno, Czech Republic.
- 773 0_
- $w MED00001639 $t European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences $x 1879-0720 $g Roč. 132, č. - (2019), s. 86-95
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30825510 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20191007 $b ABA008
- 991 __
- $a 20191011110105 $b ABA008
- 999 __
- $a ok $b bmc $g 1451403 $s 1073293
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 132 $c - $d 86-95 $e 20190228 $i 1879-0720 $m European journal of pharmaceutical sciences $n Eur. j. pharm. sci. (Print) $x MED00001639
- LZP __
- $a Pubmed-20191007